VERU INC. - 10-Q Filing Summary
Business Context and Reporting Period
Company: VERU INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Veru is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. Its primary pipeline includes enobosarm (a selective androgen receptor modulator for obesity treatment to preserve muscle mass) and sabizabulin (an anti-inflammatory agent for atherosclerotic cardiovascular disease). The company sold its commercial FC2 business in December 2024, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 |
Nine Months Ended June 30, 2026 |
Nine Months Ended June 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 (Continuing Ops) |
| Net Loss | $(6.99) million | $(15.06) million | $(24.18) million |
| Operating Expenses | $7.71 million | $20.36 million | $28.07 million |
| Cash & Equivalents (as of June 30, 2026) |
$23.88 million | ||
| Working Capital (as of June 30, 2026) |
$21.1 million | ||
| Stockholders' Equity (as of June 30, 2026) |
$28.38 million |
Note: The company has no commercial revenue from continuing operations. Net loss includes non-operating gains from equity securities.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss for the nine months ended June 30, 2026, decreased to $15.1 million from $24.2 million in the prior year period. This improvement is primarily driven by a $4.4 million gain from the change in fair value of equity securities (ONCO Warrants) and reduced operating expenses.
- Operating Expenses: Total operating expenses decreased by approximately $7.7 million year-over-year. Research and Development (R&D) expenses dropped from $12.7 million to $8.8 million due to the wind-down of the Phase 2b QUALITY study. General and Administrative (G&A) expenses fell from $15.4 million to $11.5 million, largely due to reduced share-based compensation and consulting fees.
- Discontinued Operations: The prior year period included a significant loss from discontinued operations ($7.2 million) related to the FC2 business sale. The current period shows a small gain of $0.35 million from the settlement of a dispute regarding the FC2 sale.
- Equity Financing: In October 2025, the company completed a public offering raising approximately $23.4 million in net proceeds, significantly bolstering liquidity compared to the prior period.
Guidance, Outlook, and Risks
- Clinical Progress (Enobosarm): The company completed enrollment for the Phase 2b PLATEAU clinical trial in July 2026. This study evaluates enobosarm combined with semaglutide (Wegovy) in older adults with obesity. An interim analysis is planned for Q1 2027. The FDA has indicated that incremental weight loss or physical function preservation are acceptable primary endpoints for future approval.
- Clinical Progress (Sabizabulin): The company is exploring a Phase 2 proof-of-concept study to evaluate sabizabulin for reducing inflammation in atherosclerotic cardiovascular disease, leveraging the FDA's 2023 approval of colchicine for this indication.
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the twelve months following the issuance of the financial statements. Current cash is insufficient to fund operations for that period without additional financing.
- Capital Constraints: The company is subject to the SEC "baby shelf" rule, limiting primary public offerings to one-third of its public float (approx. $21.8 million) in any 12-month period due to a public float under $75 million.
- Legal Proceedings: Multiple shareholder derivative lawsuits and a class action lawsuit (Ewing v. Veru Inc.) remain pending, alleging violations related to past statements about sabizabulin. The company cannot estimate potential losses.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the company's immediate plan to secure additional capital beyond the current $23.9 million balance.
- PLATEAU Trial Interim Data: Monitor the Q1 2027 interim analysis results for the Phase 2b PLATEAU trial, which are critical for determining the Phase 3 regulatory pathway.
- Equity Dilution: Assess the impact of the outstanding 6 million pre-funded warrants and 16.8 million Series A/B warrants (exercise price $3.00) on future dilution.
- Legal Exposure: Review the status of the pending shareholder litigation and the Clear Future lawsuit regarding the FC2 business sale for potential financial liabilities.
- ONCO Warrant Valuation: Understand the volatility of the $1.9 million investment in ONCO Warrants, which contributed significantly to the current period's non-operating gain.